Controlling Blood Pressure in Treatment Resistant Hypertension: A Pilot Study
控制难治性高血压的血压:一项试点研究
基本信息
- 批准号:8270475
- 负责人:
- 金额:$ 33.19万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-06-01 至 2015-01-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAdherenceAffectAldosterone AntagonistsAntihypertensive AgentsBehaviorBlood PressureCardiovascular DiseasesCaringClinicClinicalClinical TrialsClinical effectivenessCommunitiesCommunity Health CentersComplexConsultationsControlled Clinical TrialsDataDimensionsEffectivenessEnrollmentEnvironmentEvidence based treatmentFailureFocus GroupsFoundationsGoalsGuidelinesHealthcareHypertensionInterventionInterviewLearningLife StyleMeasurementMedicalMethodsMonitorPatient NoncompliancePatientsPatternPharmaceutical PreparationsPilot ProjectsPopulation HeterogeneityPrimary Health CareProcessProviderQuestionnairesRandomizedReninResearchResearch DesignResidenciesResistanceSafetySiteSpecialistSurveysTestingTherapeuticTrainingTraining ProgramsTreatment ProtocolsVisitabstractingarmbaseblood pressure regulationcommunity based practicecomparative effectivenesscompliance behaviordemographicsdesigneffectiveness researchevidence baseexperiencehealth disparityimprovedinsightpatient populationpost interventionsuccesstreatment as usualtreatment strategyvolunteerwhite coat hypertension
项目摘要
DESCRIPTION (provided by applicant):
Controlling Blood Pressure in Treatment Resistant Hypertension: A Pilot Study. Background: Treatment resistant hypertension (TRH), i.e., blood pressure (BP) above goal on >3 BP medications affects millions of people and contributes to health disparities. In clinical trials, where patient compliance is confirmed and BP meds are systematically titrated to attain control, ~20% of patients have TRH, which suggests limited effectiveness of current treatment strategies contributes to TRH. This pilot study examines the feasibility, safety, and preliminary effectiveness of four evidence-based approaches to improving BP control in TRH. The four strategies include adding an aldosterone antagonist in eligible patients (AAEP), renin treatment-guided therapeutics (RTGT), clinical hypertension specialist care (CHSC), and RTGT+CHSC. Hypothesis: Defining pathophysiological mechanisms (RTGT) and/or expert consultation (CHSC) will improve BP control more than 'blindly' adding an aldosterone antagonist in eligible patients (AAEP). Specific aim: Assess the feasibility, safety, and preliminary comparative effectiveness in a diverse group of patients and clinical settings of four evidence-based treatment strategies for treatment resistant hypertension (TRH) to test the hypothesis that RTGT and/or CHSC are more effective than AAEP for controlling BP in TRH. Hypothesis: Eliciting patient, provider and staff experiences and insights post intervention will identify barriers and facilitators to implementing AAEP, RTGY, and CHSC that will inform design of the demonstration study. Specific Aim. Conduct post-intervention patient questionnaires and interviews and staff and provider focus groups and an online SWOT to identify barriers and facilitators to AAEP, RTGY and CHSC that will inform the demonstration study in real world practice settings. Methods: 8 diverse clinics (>1 community health centers, single & multi-site primary care clinics, community residency training programs) that provide care for a diverse patient population will be randomized to 1 of 4 study arms. Each cilnic will enroll 18 TRH patients (36/arm). All clinics receive BpTRU monitors and training to standardize BP measurements and 'eliminate' white coat hypertension. Key study data include patient demographics, visits, BP values, meds, and lab data. Post study focus groups and strengths, weaknesses, opportunities, threats (SWOT) analysis with providers and staff and patient questionnaire and interviews will be used to evaluate several dimensions of the study and guide the demonstration study design. Significance: TRH is common medical condition, and relatively ineffective treatment regimens are a significant contributing factor. The long-term goal is to establish practical, effective, and widely replicable approaches for controlling BP in TRH and reducing clinical complications and related health disparities. (End of Abstract)
描述(由申请人提供):
控制治疗高血压中的血压:一项试点研究。背景:耐药高血压(TRH),即高于3 bp药物的血压(BP)影响数百万的人,并导致健康差异。在临床试验中,确认患者依从性并系统地滴定BP药物以获得控制,约有20%的患者患有TRH,这表明当前治疗策略的有效性有限。这项试点研究研究了四种改善TRH中BP控制的方法的可行性,安全性和初步有效性。这四种策略包括在合格患者(AAEP),肾素治疗引导的治疗药(RTGT),临床高血压专家护理(CHSC)和RTGT+CHSC中增加醛固酮拮抗剂。假设:定义病理生理机制(RTGT)和/或专家咨询(CHSC)将改善BP控制能力,而不是“盲目地”添加合格患者(AAEP)的醛固酮拮抗剂。具体目的:评估各种患者组的可行性,安全性和初步比较有效性以及四种基于证据的治疗抗药性高血压(TRH)的临床环境,以检验RTGT和/或CHSC的假设,即RTGT和/或CHSC比AAEP在TRH中更有效。假设:在干预后引起患者,提供者和员工的经验和见解将确定实施AAEP,RTGY和CHSC的障碍和促进者,这将为示范研究的设计提供信息。具体目标。进行干预后的患者问卷和访谈以及员工和提供者的焦点小组以及在线SWOT,以确定AAEP,RTGY和CHSC的障碍和促进者,这些障碍和促进者将在现实世界实践环境中为示范研究提供信息。方法:8个不同的诊所(> 1个社区卫生中心,单位和多站点初级保健诊所,社区居住培训计划),这些诊所为多样化的患者人群提供护理,将随机分为4个研究臂中的1个。每个CILNIC将注册18名TRH患者(36/ARM)。所有诊所都接受BPTRU监测和培训,以标准化BP测量并“消除”白色涂层高血压。关键研究数据包括患者人口统计,访问,BP值,药物和实验室数据。研究后的焦点小组和优势,劣势,机会,威胁(SWOT)分析与提供者和员工以及患者问卷以及访谈将用于评估研究的几个方面,并指导示范研究设计。意义:TRH是常见的医学状况,相对无效的治疗方案是重要的因素。长期目标是建立实用,有效且可复制的方法来控制TRH中的BP并减少临床并发症和相关的健康差异。 (抽象的结尾)
项目成果
期刊论文数量(8)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Hypertension in the United States, 1999 to 2012: progress toward Healthy People 2020 goals.
- DOI:10.1161/circulationaha.114.010676
- 发表时间:2014-11-04
- 期刊:
- 影响因子:37.8
- 作者:Egan BM;Li J;Hutchison FN;Ferdinand KC
- 通讯作者:Ferdinand KC
Achievement of cardiometabolic goals in aware hypertensive patients in Spain: implications for population health.
西班牙意识高血压患者实现心脏代谢目标:对人口健康的影响。
- DOI:10.1161/hypertensionaha.112.198994
- 发表时间:2012
- 期刊:
- 影响因子:0
- 作者:Egan,BrentM
- 通讯作者:Egan,BrentM
Role of aldosterone blockade in resistant hypertension.
醛固酮阻断在难治性高血压中的作用。
- DOI:10.1016/j.semnephrol.2014.04.004
- 发表时间:2014
- 期刊:
- 影响因子:3.3
- 作者:Egan,BrentM;Li,Jiexiang
- 通讯作者:Li,Jiexiang
Comparative effectiveness research in the "real" world: lessons learned in a study of treatment-resistant hypertension.
“现实”世界中的比较有效性研究:难治性高血压研究中的经验教训。
- DOI:10.1016/j.jash.2012.12.002
- 发表时间:2013
- 期刊:
- 影响因子:0
- 作者:Laken,MarilynA;Dawson,Rosalind;Engelman,Otis;Lovelace,Oscar;Way,Charles;Egan,BrentM
- 通讯作者:Egan,BrentM
Effectiveness of a tailored behavioral intervention to improve hypertension control.
量身定制的行为干预措施对改善高血压控制的有效性。
- DOI:10.1161/hypertensionaha.114.04650
- 发表时间:2015
- 期刊:
- 影响因子:0
- 作者:Egan,BrentM
- 通讯作者:Egan,BrentM
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
BRENT M EGAN其他文献
BRENT M EGAN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('BRENT M EGAN', 18)}}的其他基金
Controlling Blood Pressure in Treatment Resistant Hypertension: A Pilot Study
控制难治性高血压的血压:一项试点研究
- 批准号:
8031912 - 财政年份:2011
- 资助金额:
$ 33.19万 - 项目类别:
PROTEOMIC ANALYSIS OF BLOOD: ZN-ALPHA-2-GLYCOPROTEIN AS A BIOMARKER FOR CACHE
血液蛋白质组分析:ZN-ALPHA-2-糖蛋白作为缓存生物标志物
- 批准号:
7719594 - 财政年份:2008
- 资助金额:
$ 33.19万 - 项目类别:
INSULIN RESISTANCE AND CARDIOVASCULAR RISK FACTORS
胰岛素抵抗和心血管风险因素
- 批准号:
6526989 - 财政年份:2000
- 资助金额:
$ 33.19万 - 项目类别:
INSULIN RESISTANCE AND CARDIOVASCULAR RISK FACTORS
胰岛素抵抗和心血管风险因素
- 批准号:
6388643 - 财政年份:2000
- 资助金额:
$ 33.19万 - 项目类别:
INSULIN RESISTANCE AND CARDIOVASCULAR RISK FACTORS
胰岛素抵抗和心血管风险因素
- 批准号:
6657302 - 财政年份:2000
- 资助金额:
$ 33.19万 - 项目类别:
INSULIN RESISTANCE AND CARDIOVASCULAR RISK FACTORS
胰岛素抵抗和心血管风险因素
- 批准号:
6786649 - 财政年份:2000
- 资助金额:
$ 33.19万 - 项目类别:
INSULIN RESISTANCE AND CARDIOVASCULAR RISK FACTORS
胰岛素抵抗和心血管风险因素
- 批准号:
6798949 - 财政年份:2000
- 资助金额:
$ 33.19万 - 项目类别:
相似国自然基金
坚持还是转型?反馈驱动的创业者机会信念认知更新及响应决策机理
- 批准号:
- 批准年份:2022
- 资助金额:45 万元
- 项目类别:面上项目
坚持还是转型?反馈驱动的创业者机会信念认知更新及响应决策机理
- 批准号:72272131
- 批准年份:2022
- 资助金额:45.00 万元
- 项目类别:面上项目
不确定性下创业团队能量和抗逆力对创业坚持的权变影响研究
- 批准号:72162025
- 批准年份:2021
- 资助金额:29 万元
- 项目类别:地区科学基金项目
创造性思维中灵活性和坚持性动态交互的神经基础
- 批准号:
- 批准年份:2021
- 资助金额:30 万元
- 项目类别:青年科学基金项目
创造性思维中灵活性和坚持性动态交互的神经基础
- 批准号:32100850
- 批准年份:2021
- 资助金额:24.00 万元
- 项目类别:青年科学基金项目
相似海外基金
Promesa: Urban gardening and peer nutritional counseling to improve HIV care outcomes among people with food insecurity in the Dominican Republic
Promesa:城市园艺和同伴营养咨询可改善多米尼加共和国粮食不安全人群的艾滋病毒护理结果
- 批准号:
10698434 - 财政年份:2023
- 资助金额:
$ 33.19万 - 项目类别:
Previvors Recharge: A Resilience Program for Cancer Previvors
癌症预防者恢复活力计划:癌症预防者恢复力计划
- 批准号:
10698965 - 财政年份:2023
- 资助金额:
$ 33.19万 - 项目类别:
Implementing Evidence-Based Treatment for Common Mental Disorders in HIV Clinics in Ukraine
在乌克兰艾滋病毒诊所对常见精神疾病实施循证治疗
- 批准号:
10762576 - 财政年份:2023
- 资助金额:
$ 33.19万 - 项目类别:
Understand and mitigating the influence of extreme weather events on HIV outcomes: A global investigation
了解并减轻极端天气事件对艾滋病毒感染结果的影响:一项全球调查
- 批准号:
10762607 - 财政年份:2023
- 资助金额:
$ 33.19万 - 项目类别:
Examining the Effectiveness of the Early Start Denver Model in Community Programs serving Young Autistic Children
检查早期开始丹佛模式在为自闭症儿童服务的社区项目中的有效性
- 批准号:
10725999 - 财政年份:2023
- 资助金额:
$ 33.19万 - 项目类别: